Literature DB >> 24503766

Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease.

Jan Däbritz1.   

Abstract

Current literature consolidates the view of Crohn's disease (CD) as a form of immunodeficiency highlighting dysregulation of intestinal innate immunity in the pathogenesis of CD. Intestinal macrophages derived from blood monocytes play a key role in sustaining the innate immune homeostasis in the intestine, suggesting that the monocyte/macrophage compartment might be an attractive therapeutic target for the management of CD. Granulocyte macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that also promotes myeloid cell activation, proliferation, and differentiation. GM-CSF has a protective effect in human CD and mouse models of colitis. However, the role of GM-CSF in immune and inflammatory reactions in the intestine is not well defined. Beneficial effects exerted by GM-CSF during intestinal inflammation could relate to modulation of the mucosal barrier function in the intestine, including epithelial cell proliferation, survival, restitution, and immunomodulatory actions. The aim of this review is to summarize potential mechanistic roles of GM-CSF in intestinal innate immune cell homeostasis and to highlight its central role in maintenance of the intestinal immune barrier in the context of immunodeficiency in CD.

Entities:  

Keywords:  cytokine autoantibodies; dendritic cells; epithelial barrier; immune response; immunodeficiency; myeloid-derived suppressor cells; pathogenesis

Mesh:

Substances:

Year:  2014        PMID: 24503766     DOI: 10.1152/ajpgi.00409.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

1.  Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice.

Authors:  Andrew J McDermott; Charles R Frank; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Gut Microbes       Date:  2014-07-21

Review 2.  Novel insights in preventing Gram-negative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis of the immune system.

Authors:  Dong Xu; Manzhi Zhao; Yuhu Song; Jianxin Song; Yuancheng Huang; Junshuai Wang
Journal:  Hepatol Int       Date:  2014-11-21       Impact factor: 6.047

Review 3.  GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.

Authors:  Palash Bhattacharya; Muthusamy Thiruppathi; Hatem A Elshabrawy; Khaled Alharshawi; Prabhakaran Kumar; Bellur S Prabhakar
Journal:  Cytokine       Date:  2015-06-22       Impact factor: 3.861

Review 4.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 5.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

Review 6.  Targeting GM-CSF in inflammatory diseases.

Authors:  Ian P Wicks; Andrew W Roberts
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543

7.  GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease.

Authors:  Jan Däbritz
Journal:  Mol Cell Pediatr       Date:  2015-12-01

Review 8.  Pivotal roles of GM-CSF in autoimmunity and inflammation.

Authors:  Aoi Shiomi; Takashi Usui
Journal:  Mediators Inflamm       Date:  2015-03-08       Impact factor: 4.711

9.  Molecular and Histological Profiling Reveals an Innate-Shaped Immune Microenvironment in Solitary Juvenile Polyps.

Authors:  Daniel Zysset; Matteo Montani; Johannes Spalinger; Susanne Schibli; Inti Zlobec; Christoph Mueller; Christiane Sokollik
Journal:  Clin Transl Gastroenterol       Date:  2021-06-01       Impact factor: 4.488

10.  Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells.

Authors:  Jan Däbritz; Louise M Judd; Heather V Chalinor; Trevelyan R Menheniott; Andrew S Giraud
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.